Trial of Third Party Donor Derived CMVpp65 Specific T-cells for The Treatment of CMV Infection or Persistent CMV Viremia After Allogeneic Hematopoietic Stem Cell Transplantation

NCT02136797 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

77

Enrollment

OTHER

Sponsor class

Conditions

CMV Infection
Persistent CMV Viremia

Interventions

BIOLOGICAL: CMVpp65 Specific T-cells

Sponsor

Memorial Sloan Kettering Cancer Center